You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Article metrics

Article menu

Download PDFPDF

Case report
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

 

Online download statistics by month:

Online download statistics by month: May 2023 to March 2026

AbstractFullPdf
May 202331231455
Jun 202316016028
Jul 202313113139
Aug 202315615638
Sep 2023808114
Oct 2023868724
Nov 202312112130
Dec 2023909138
Jan 2024525225
Feb 2024555522
Mar 2024515140
Apr 2024494924
May 2024596023
Jun 2024646333
Jul 2024596018
Aug 2024474517
Sep 2024585827
Oct 2024525221
Nov 2024565721
Dec 20249310520
Jan 2025494921
Feb 2025848624
Mar 2025595930
Apr 2025686818
May 2025505121
Jun 2025414113
Jul 2025110
Aug 2025110
Feb 2026110
Mar 2026110
Total21862206684